With drug candidates in all stages of clinical development, Regeneron has the expertise, infrastructure, and corporate collaborations needed to
move these candidates through the development process.
Regeneron has eight investigational product candidates progressing through all stages of human clinical trials for a diverse set of serious diseases including cancer, eye diseases, inflammatory diseases, pain, cardiovascular/metabolic diseases, and allergic conditions. The Company draws on strong internal capabilities and its collaborations with the sanofi-aventis Group and Bayer HealthCare to manage these significant clinical efforts.
Recent News
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy
Regeneron Provides Initial Data on Two Antibody Product Candidates
VEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema
This section discusses the Regeneron pipeline of drug candidates currently
undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates
have not been evaluated by any regulatory authorities for
the indications described in this section.